• Explore /
  • Poster
  • / Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).

Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).

Abstract Poster

Authors

null

Chloe Lim

Department of Medicine, University of Calgary, Calgary, AB, Canada;

Chloe Lim , Carla Pires Amaro , Philip Q. Ding , Winson Y. Cheung , Vincent C. Tam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 553)

DOI

10.1200/JCO.2023.41.4_suppl.553

Abstract #

553

Poster Bd #

D5

Abstract Disclosures

Similar Posters

First Author: Julien Edeline

First Author: Claudia A.M. Fulgenzi

First Author: Julien Edeline

First Author: William Joseph Chapin